A healthcare client was testing a new diabetes treatment in early clinical trials. Though the primary indication was in type 2, research was needed to determine whether or not to pursue an indication in the type 1 space. There was also a need to understand the most viable patient segments for the product, as well as to anticipate what market uptake would be when launched.
A multi-phase research program was conducted with a patient flow/segmentation study via an online chart audit approach, which identified and quantified the most viable patient segments. This was followed by qualitative research to understand drivers of prescribing the medication for specific patient types. Finally, a market share and claims optimization study was conducted using a discrete choice methodology.
The research provided insight into expected uptake of the product under various competitive and order of entry market scenarios.